Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.35 | 1.93 |
NAV | ₹15.16 | ₹35.43 |
Fund Started | 18 Oct 2021 | 25 Jun 2018 |
Fund Size | ₹216.51 Cr | ₹4917.81 Cr |
Exit Load | Exit load of 1% if redeemed within 12 months. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 10.97% | 17.86% |
3 Year | 17.31% | 22.62% |
5 Year | - | 26.56% |
1 Year
3 Year
5 Year
Equity | 93.44% | 98.79% |
Cash | 6.56% | 1.21% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 16.00% |
Lupin Ltd. | 6.34% |
Apollo Hospitals Enterprise Ltd. | 5.03% |
Divi's Laboratories Ltd. | 4.89% |
Suven Pharmaceuticals Ltd. | 4.88% |
Aurobindo Pharma Ltd. | 4.78% |
Max Healthcare Institute Ltd. | 4.05% |
Torrent Pharmaceuticals Ltd. | 3.85% |
Dr. Reddy's Laboratories Ltd. | 3.39% |
Alkem Laboratories Ltd. | 2.91% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.56% |
Cipla Ltd. | 9.71% |
Dr. Reddy's Laboratories Ltd. | 8.28% |
Divi's Laboratories Ltd. | 6.05% |
Aurobindo Pharma Ltd. | 4.87% |
Lupin Ltd. | 4.47% |
Alkem Laboratories Ltd. | 3.87% |
Zydus Lifesciences Ltd. | 3.19% |
Gland Pharma Ltd. | 3.19% |
Mankind Pharma Ltd. | 2.81% |
Name | Dhimant Shah | Dharmesh Kakkad |
Start Date | 01 Dec 2022 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 18 Oct 2021 | 25 Jun 2018 |
Description
Launch Date